title: Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
authors.forename: Wee J
authors.initials: WJ
authors.lastname: Chng
authors.forename: George
authors.initials: G
authors.lastname: Mulligan
authors.forename: Barbara
authors.initials: B
authors.lastname: Bryant
authors.forename: Leif
authors.initials: L
authors.lastname: Bergsagel
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000401:mortality*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D011003:Ploidies; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011719:Pyrazines; D000069286:Bortezomib